Skip to main content
Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · LYRA ISIN · US55234L1052 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2022-05-10 Interim / Quarterly Rep…
Country US United States of America
Listing US LYRA

About Lyra Therapeutics, Inc.

https://lyratherapeutics.com/

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company that develops and commercializes innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's product candidates are long-acting, anti-inflammatory sinonasal implants designed to deliver medication directly to sinonasal tissues. This approach aims to provide a new, long-lasting treatment option for patients with this debilitating inflammatory disease, targeting tissues that are not easily accessible with conventional therapeutic methods.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2022
2022-05-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2022, reporting the company's financial results for the quarter ended March 31, 2022. It includes a press release as Exhibit 99.1 announcing these results. The text explicitly states that the press release is furnished and not filed, and the document is a current report rather than a full quarterly or annual report. The content corresponds to an initial announcement of quarterly financial results, which matches the definition of an Earnings Release (ER). The document length is 3533 characters, which is consistent with a brief announcement rather than a full report. Therefore, the correct classification is Earnings Release (ER).
2022-05-10 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes information about voting on board members and ratification of auditors, typical content for proxy solicitation materials. The text references the Annual Meeting and voting instructions, but does not contain financial statements or detailed financial analysis. It also mentions the availability of the Form 10-K and proxy statement online, indicating this document is proxy solicitation material rather than the annual report itself. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length (5119 characters) and content confirm it is not a brief announcement or a full annual report but proxy materials. Confidence is high due to clear identification of Schedule 14A and proxy voting content.
2022-04-27 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-27 English
Regulatory Filings 2022
Regulatory Filings
2022-04-26 English
SC 13D/A
Major Shareholding Notification
2022-04-22 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.